A dual antagonist of CCR2 and CCR5
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical development for cardiovascular.
参考文献:
[1]. Norman P. et al. A dual CCR2/CCR5 chemokine antagonist, BMS-813160 Evaluation of WO2011046916. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
没有评价数据